Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06439966 | Expanded Access to ABBV-787 | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT05269771 | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 8 | Nov 5, 2025 | clinicaltrials |
| NCT03420430 |
| Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care |
| no longer available |
| — |
| — |
| Genelux CorporationINDUSTRY |
| 1 |
| Sep 25, 2024 |
| clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03592576 | Expanded Access to Navitoclax | no longer available | — | — | AbbVieINDUSTRY | 0 | May 6, 2024 | clinicaltrials |
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT00423826 | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease | no longer available | — | — | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Feb 29, 2016 | clinicaltrials |
| NCT01549548 | Compassionate Use Ponatinib | no longer available | — | — | OHSU Knight Cancer InstituteOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00302016 | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 34 | Aug 26, 2011 | clinicaltrials |
| NCT00413270 | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials